Information Provided By: 
Fly News Breaks for March 13, 2019
LGND
Mar 13, 2019 | 10:20 EDT
Roth Capital analyst Scott Henry raised his price target for Ligand Pharmaceuticals to $190 from $180 following yesterday's analyst meeting. The company's base business is better than expected, Henry tells investors in a research note. The analyst upped his 2020 revenue target to $126M from $118M and sees upside to Ligand's targets based on milestones. He reiterates a Buy rating on the stock.
News For LGND From the Last 2 Days
There are no results for your query LGND
